Yvonne McGrath
Chief Tech/Sci/R&D Officer chez ITEOS THERAPEUTICS, INC.
Fortune : 422 840 $ au 31/03/2024
Profil
Yvonne McGrath is currently the Chief Scientific Officer at iTeos Therapeutics, Inc. She previously worked as the Director & Chief Scientific Officer at Complix NV from 2014 to 2020 and as the Head-Development at Immunocore Holdings Plc from 2010 to 2014.
Dr. McGrath holds a doctorate degree from The University of Wales, which she obtained in 2000.
She also has an undergraduate degree from Queen's University Belfast.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ITEOS THERAPEUTICS, INC.
0,09% | 07/03/2024 | 31 000 ( 0,09% ) | 422 840 $ | 31/03/2024 |
Postes actifs de Yvonne McGrath
| Sociétés | Poste | Début |
|---|---|---|
| ITEOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2020 |
Anciens postes connus de Yvonne McGrath
| Sociétés | Poste | Fin |
|---|---|---|
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Chief Tech/Sci/R&D Officer | 01/04/2020 |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 01/04/2014 |
Formation de Yvonne McGrath
| The University of Wales | Doctorate Degree |
| Queen’S University Belfast | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ITEOS THERAPEUTICS, INC. | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
